News

Nasodine now patented in 26 countries

25 May 2022

Nasodine now patented in 26 countries

Read More

Firebrick appoints Dr Richard Treagus as director

25 May 2022

Firebrick appoints Dr Richard Treagus as director

Read More

Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine

17 May 2022

Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine

Read More

Peter Molloy discusses the common cold trial on global finance platform Grafa

4 May 2022

Peter Molloy discusses the common cold trial on global finance platform Grafa

Read More

Nasodine Phase 3 common cold trial underway

3 May 2022

Nasodine Phase 3 common cold trial underway

Read More

Nasodine trial in COVID-19 started

26 Apr 2022

Nasodine trial in COVID-19 started

Read More

Firebrick to file appeal seeking immediate approval of Nasodine

1 Mar 2022

Firebrick to file appeal seeking immediate approval of Nasodine

Read More

US Patent Granted for Nasodine in COVID-19

17 Feb 2022

US Patent Granted for Nasodine in COVID-19

Read More

Peter Molloy on the Nasodine SARS-CoV-2 data and the Firebrick vision

10 Feb 2022

Peter Molloy on the Nasodine SARS-CoV-2 data and the Firebrick vision

Read More

Nasodine in vitro and pilot human COVID-19 studies published

10 Feb 2022

Nasodine in vitro and pilot human COVID-19 studies published

Read More

Peter Molloy on Firebrick’s successful ASX debut and plans for Nasodine

3 Feb 2022

Peter Molloy on Firebrick’s successful ASX debut and plans for Nasodine

Read More

South African trial of Nasodine in COVID-19 receives local approval to proceed

1 Feb 2022

South African trial of Nasodine in COVID-19 receives local approval to proceed

Read More

Firebrick launch on ASX receives national media attention

28 Jan 2022

Firebrick launch on ASX receives national media attention

Read More

Firebrick Pharma to debut on the ASX

27 Jan 2022

Firebrick Pharma to debut on the ASX

Read More